DALLAS, June 12, 2017 (GLOBE NEWSWIRE) -- Arog Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, today announced that it will feature two poster presentations and a satellite symposium on the company’s lead product candidate, crenolanib, at the 22nd Congress of the European Hematology Association (EHA), taking place June 22-25, 2017 in Madrid, Spain. Crenolanib continues to demonstrate best-in-class properties in the treatment of acute myeloid leukemia (AML) with FLT3 mutations.
Satellite Symposium
Title: Targeting the FLT-3 Pathway in AML: Evolution of Next Generation Tyrosine Kinase Inhibitors
Session Title: Satellite Symposium
Date: Thursday, June 22, 2017
Time: 7:00 – 9:00 PM CEST
Location: Hall D
Poster Presentations
Title: Functional Assessment of Novel Diagnostic FLT3 Mutations and Inhibition by Kinase Inhibitors
Authors: Katherine Tarlock, Tiffany A. Hylkema, Jessica A. Pollard, M. Eva Hansen, Rhonda Ries, Richard Sweat, Soheil Meshinchi
Session Title: Acute Myeloid Leukemia – Biology 2
Speaker: Katherine Tarlock
Date: Friday, June 23, 2017
Time: 5:15 – 6:45 PM CEST
Location: Hall 7
Abstract Code: P184
Title: Variant FLT3 Mutations can be Eradicated by Cytarabine/Anthracycline/Crenolanib Induction in Adult Patients with Newly Diagnosed FLT3 (ITD/TKD) Mutant AML
Authors: Eunice Wang, Richard Stone, Robert Collins, Trishala Agrawal, Vinoo Urity, Martin Tallman
Session Title: Acute Myeloid Leukemia – Clinical 4
Speaker: Eunice Wang
Date: Saturday, June 24, 2017
Time: 5:30 – 7:00 PM CEST
Location: Hall 7
Abstract Code: P552
About Arog Pharmaceuticals, Inc.
Arog Pharmaceuticals is a private, clinical-stage biopharmaceutical company that has leveraged its platform of benzimidazole derivatives to develop a robust drug pipeline of orally available, potent, and selective small molecule type I tyrosine kinase inhibitors (TKIs). Arog is undergoing pivotal, randomized Phase III trials of its lead molecule, crenolanib. For more information, please visit the company’s website, http://www.arogpharma.com.
About Crenolanib
Arog’s lead molecule, crenolanib, is a type I TKI that selectively and potently inhibits signaling of wild-type and mutant isoforms of class III receptor tyrosine kinases (RTKs), FLT3 and PDGFRα/β. Crenolanib has an established record of patient safety and has been used to treat over 350 patients. Crenolanib is currently being clinically investigated in combination with standard induction or salvage chemotherapy in patients with FLT3 mutant acute myeloid leukemia (AML).
About FLT3
FLT3 is a class III RTK, and its signaling is considered important for the normal development of hematopoietic stem cells and progenitor cells. The FLT3 gene is one of the most frequently mutated genes (~30%) in AML. One such mutation, internal tandem duplications of FLT3 (FLT3-ITD), is a prognostic indicator associated with adverse disease outcome.